New study supports testing of Merck’s Ebola vaccine in DRC outbreak
New data supports the idea that Merck’s Ebola vaccine Ervebo, licensed to target the Zaire species of ebolaviruses, could also offer some protection against another.
Story detail
Read the key details here, then continue on the original publisher.
New data supports the idea that Merck’s Ebola vaccine Ervebo, licensed to target the Zaire species of ebolaviruses, could also offer some protection against another.
Join our channel to receive the latest headlines and breaking stories as soon as they are published.
Comments (0)
Join the conversation. Comments are rate-limited, secured, and GDPR-compliant.
No comments yet. Be the first to share your thoughts!